> Vernalis paid £10 million ($13 million) to terminate its agreement with Tris Pharma. The decision follows regulatory setbacks for products covered by the agreement. Release (PDF)
> Syncona founded two gene therapy startups. The British life science investor committed $23 million to SwanBio and $12 million to Orbit Biomedical. Statement (PDF)
> Newron Pharmaceuticals delayed a readout from its phase 3 Rett syndrome clinical trial by up to six months. Statement
> PharmaMar asked to change the primary endpoint of its phase 3 lung cancer trial. Moving from progression-free to overall survival will delay the readout until the second half of next year. Release (PDF)
> Motif Bio completed the rolling NDA for its antibiotic iclaprim. Statement